TY - JOUR
AU - G. T. Lapham
AU - J. F. Bobb
AU - C. Luce
AU - M. M. Oliver
AU - L. K. Hamilton
AU - N. Hyun
AU - K. A. Hallgren
AU - T. E. Matson
A1 - 
AB - BACKGROUND: Valid, single-item cannabis screens for the frequency of past-year use (SIS-C) can identify patients at risk for cannabis use disorder (CUD); however, the prevalence of CUD for patients who report varying frequencies of use in the clinical setting remains unexplored. OBJECTIVE: Compare clinical responses about the frequency of past-year cannabis use to typical use and CUD severity reported on a confidential survey. PARTICIPANTS: Among adult patients in an integrated health system who completed the SIS-C as part of routine care (3/28/2019-9/12/2019; n = 108,950), 5000 were selected for a confidential survey using stratified random sampling. Among 1688 respondents (34% response rate), 1589 who reported past-year cannabis use on the SIS-C were included. MAIN MEASURES: We compared patients with varying frequency of cannabis use on the SIS-C (< monthly, monthly, weekly, daily) to survey responses on the Composite International Diagnostic Interview Substance Abuse Module for CUD (any and moderate-severe CUD) and cannabis exposure measures (typical use per-week, per-day). Adjusted multinomial (categorical) and logistic regression (binary), weighted for population estimates, estimated the prevalence of outcomes across frequencies. KEY RESULTS: Patients were predominantly middle-aged (mean = 43.3 years [SD = 16.9]), male (51.8%), white (78.2%), non-Hispanic (94.0%), and commercially insured (68.9%). The prevalence of any and moderate-severe CUD increased with greater frequency of past-year cannabis use reported on the SIS-C (p-values < 0.001) and ranged from 12.7% (6.3-19.2%) and 0.9% (0.0-2.7%) for < monthly to 44.6% (41.4-47.7%) and 20.3% (17.8-22.9%) for daily use, respectively. Greater frequency of use on the SIS-C in the clinical setting corresponded with greater per-week and per-day use on the confidential survey. CONCLUSIONS: Among patients who reported past-year cannabis use as part of routine screening, the prevalence of CUD and other cannabis exposure measures increased with greater frequency of cannabis use, underscoring the utility of brief cannabis screens for identifying patients at risk for CUD.
AD - Kaiser Permanente Washington Health Research Institute, Seattle, USA. gwen.t.lapham@kp.org.; Department of Health Systems and Population Health, University of Washington, Seattle, WA, USA. gwen.t.lapham@kp.org.; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. gwen.t.lapham@kp.org.; Kaiser Permanente Washington Health Research Institute, Seattle, USA.; Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.; Department of Health Systems and Population Health, University of Washington, Seattle, WA, USA.
AN - 39446234
BT - J Gen Intern Med
C5 - Opioids & Substance Use
CP - 5
DA - Apr
DO - 10.1007/s11606-024-09061-6
DP - NLM
ET - 20241024
IS - 5
JF - J Gen Intern Med
LA - eng
N2 - BACKGROUND: Valid, single-item cannabis screens for the frequency of past-year use (SIS-C) can identify patients at risk for cannabis use disorder (CUD); however, the prevalence of CUD for patients who report varying frequencies of use in the clinical setting remains unexplored. OBJECTIVE: Compare clinical responses about the frequency of past-year cannabis use to typical use and CUD severity reported on a confidential survey. PARTICIPANTS: Among adult patients in an integrated health system who completed the SIS-C as part of routine care (3/28/2019-9/12/2019; n = 108,950), 5000 were selected for a confidential survey using stratified random sampling. Among 1688 respondents (34% response rate), 1589 who reported past-year cannabis use on the SIS-C were included. MAIN MEASURES: We compared patients with varying frequency of cannabis use on the SIS-C (< monthly, monthly, weekly, daily) to survey responses on the Composite International Diagnostic Interview Substance Abuse Module for CUD (any and moderate-severe CUD) and cannabis exposure measures (typical use per-week, per-day). Adjusted multinomial (categorical) and logistic regression (binary), weighted for population estimates, estimated the prevalence of outcomes across frequencies. KEY RESULTS: Patients were predominantly middle-aged (mean = 43.3 years [SD = 16.9]), male (51.8%), white (78.2%), non-Hispanic (94.0%), and commercially insured (68.9%). The prevalence of any and moderate-severe CUD increased with greater frequency of past-year cannabis use reported on the SIS-C (p-values < 0.001) and ranged from 12.7% (6.3-19.2%) and 0.9% (0.0-2.7%) for < monthly to 44.6% (41.4-47.7%) and 20.3% (17.8-22.9%) for daily use, respectively. Greater frequency of use on the SIS-C in the clinical setting corresponded with greater per-week and per-day use on the confidential survey. CONCLUSIONS: Among patients who reported past-year cannabis use as part of routine screening, the prevalence of CUD and other cannabis exposure measures increased with greater frequency of cannabis use, underscoring the utility of brief cannabis screens for identifying patients at risk for CUD.
PY - 2025
SN - 0884-8734 (Print); 0884-8734
SP - 1039
EP - 1047+
ST - Prevalence of Cannabis Use Disorder Among Primary Care Patients with Varying Frequency of Past-Year Cannabis Use
T1 - Prevalence of Cannabis Use Disorder Among Primary Care Patients with Varying Frequency of Past-Year Cannabis Use
T2 - J Gen Intern Med
TI - Prevalence of Cannabis Use Disorder Among Primary Care Patients with Varying Frequency of Past-Year Cannabis Use
U1 - Opioids & Substance Use
U3 - 10.1007/s11606-024-09061-6
VL - 40
VO - 0884-8734 (Print); 0884-8734
Y1 - 2025
ER -